More News

Nuvalent to be acquired by GSK for $10.6bn

Jim Cornall -
Nuvalent, Inc. has entered into a definitive agreement to be acquired by GSK for $10.6bn. Nuvalent is a clinical-stage precision...

FCS Foundation becomes The Foundation for Triglyceride Disorders

Jim Cornall -
The FCS Foundation has rebranded to The Foundation for Triglyceride Disorders, reflecting the organisation's expanded commitment to supporting individuals...

IND approval in China for autoimmune disease treatment

Jim Cornall -
Antengene Corporation Limited has announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND)...

Partnership looks to advance rotavirus vaccine development

Jim Cornall -
SK bioscience has announced that, after entering into a license agreement with the U.S. Centers for Disease Control and...

Integrating genetic origin data with tumour analyses enables better prediction of survival

Jim Cornall -
New research presented at the annual conference of the European Society of Human Genetics shows that a cancer patient’s...

Autoimmune vicious circle in Sjögren’s disease

Jim Cornall -
Sjögren’s disease is a chronic autoimmune disorder that affects millions of people worldwide. In patients with this disease, the...

European consortium awarded grant to develop novel delivery technique for nucleic acid therapeutics

Jim Cornall -
A European consortium has been awarded Eurostars funding for WiFIX, a project that aims to overcome the current delivery...

Laverock Therapeutics reports key oncology research milestones

Jim Cornall -
Laverock Therapeutics has announced key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications....

Base to Base biotech podcast 63: Cell and gene therapy logistics, and turning back the Parkinson’s clock

Jim Cornall -
This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with...

Sofinnova Partners collaborating with AWS to scale AI in life sciences innovation

Jim Cornall -
Life sciences venture capital firm Sofinnova Partners has announced a collaboration with Amazon Web Services (AWS), to embed AI...

Mitochondria may help immune cells fight bacteria by changing shape

Jim Cornall -
Animals have several built-in ways to defend themselves against infection. A new study by FMI researchers and their collaborators...

First gene therapy delivers missing gene to infant’s brain

Jim Cornall -
An eight-month-old infant with a severe genetic epilepsy has become the first patient in the world to receive an...

New therapy may reverse autism-related brain deficits

Jim Cornall -
Researchers have identified a promising new therapeutic strategy for autism spectrum disorder (ASD). A research team led by Kim...

Biomarker-guided immunosuppression following kidney transplantation successfully tested

Jim Cornall -
An international research team coordinated by the Medical University of Vienna has demonstrated in a clinical trial that Torque-Teno-virus-guided...

Data show cardiometabolic benefits of Type 2 diabetes treatment

Jim Cornall -
Sparrow Pharmaceuticals, Inc. has announced positive phase 2 clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1...

Orphan Drug Designation for potential best-in-class ADC for sarcoma

Jim Cornall -
SOTIO Biotech has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

FDA Breakthrough Therapy Designation for spinal muscular atrophy treatment

Jim Cornall -
Biogen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for...

Servier acquiring Edgewise Therapeutics’ muscular dystrophy business

Jim Cornall -
Servier has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. for up to...

Antibody fragment prevents haemorrhages associated with new Alzheimer’s treatments

Jim Cornall -
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (Kisunla,...

Fast Track Designation for Lynch syndrome-associated cancers treatment

Jim Cornall -
Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, has announced that the U.S....

Positive data from linear IgA disease study

Jim Cornall -
JJP Biologics has announced positive interim data from its ongoing phase 1b trial evaluating nebaprubart, also known as JJP-1212,...